SpliceBio

SpliceBio is a cutting-edge genetic medicine company specializing in Protein Splicing as a novel modality for gene therapy. Rooted in advancements from the Muir Lab at Princeton University, the company leverages over two decades of pioneering research in intein and protein engineering. SpliceBio is focused on delivering next-generation genetic therapies, with an emphasis on tackling diseases arising from large gene mutations. The company recently secured $135 million in Series B financing, spearheaded by EQT Life Sciences and Sanofi Ventures among others, to advance its leading program, SB-007, aimed at treating Stargardt Disease. Led by co-founders Dr. Miquel Vila-Perelló and Dr. Silvia Frutos, who have extensive backgrounds in protein engineering and intein technology, the company drives forward with innovation in precise and efficient delivery solutions for genetic medicines. Their work is crucial in bridging cutting-edge science to therapeutic development, heralding a new era of genetic treatments.